<DOC>
	<DOCNO>NCT00959387</DOCNO>
	<brief_summary>Over last 30 year , induction chemotherapy ( IC ) become important management patient locally advanced HNSCC ( LAHNSCC ) , particularly since introduction taxanes . The result report TAX 323 TAX 324 trial indicate TPF regimen ( docetaxel , cisplatin 5-fluorouracil ) improve overall survival compare PF regimen ( cisplatin 5-fluorouracil ) , TPF regimen globally accept induction regimen treatment LAHNSCC . However , TPF regimen associate high toxicity rate , patient frequently decline cisplatin concurrent radiotherapy require use infusion pump central venous catheter . Extensive effort ongoing identify alternative scheme less toxic TPF regimen effective LAHNSCC safely allow use definitive concurrent treatment base cisplatin radiotherapy .</brief_summary>
	<brief_title>Induction Chemotherapy Advanced Head Neck Cancer</brief_title>
	<detailed_description>This non-randomized phase II trial evaluate safety , feasibility response rate concurrent therapy ( cisplatin radiotherapy ) three cycle IC regimen base combination cisplatin plus paclitaxel without 5-fluorouracil ( 5FU ) ( thereby avoid infusion pump central venous catheter ) LAHNSCC patient high tumor burden . The patient stratify tumor subsite ( oropharynx hypopharynx/larynx ) tumor resectable status ( resectable irresectable advance squamous cell ) .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm locally advanced squamous cell carcinoma head neck ( stage III IV ) eligible chemoradiotherapy . Presence measurable disease ≥ 18 year ECOG performance status : 02 Adequate bone marrow function evidence : absolute neutrophil count ≥ 1.5 x 109/L ; platelet count ≥ 100 x 109/L hemoglobin ≥ 90 g/L Adequate renal function . Adequate hepatic function . Patients legal representative must able read , understand provide write informed consent participate study . Any previous chemotherapy radiotherapy Patients know hypersensitivity paclitaxel cisplatin Patients receive concurrent investigational , biological immune therapy Concomitant administration high dos systemic corticosteroid Known HIV Hepatitis B C ( active , previously treat ; test require ) Uncontrolled CNS disease ( e.g. , seizure control standard medical therapy ) Clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>induction chemotherapy</keyword>
</DOC>